Brigitte C Widemann, M.D.
National Cancer Institute (NCI) · National Cancer Institute, National Institutes of Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
20
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
0
PubMed author-name match
Trials
Studies that name Brigitte C Widemann, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:59 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06222203 · Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)National Cancer Institute (NCI) · recruiting · Neurofibromatosis 1, Nerve Sheath Neoplasms · principal investigator
- N/ANCT04774289 · Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)National Cancer Institute (NCI) · completed · Neurofibromatosis 1, Peripheral Nerve Neoplasms, Malignant · principal investigator
- Ph1/Ph2NCT04750928 · Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical NeurofibromasNational Cancer Institute (NCI) · recruiting · Neurofibromatosis 1 · principal investigator
- Ph2NCT03109301 · Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)National Cancer Institute (NCI) · withdrawn · Neoplasms, Nerve Tissue, Neurofibromatosis 1, Heredodegenerative Disorders, Nervous System · principal investigator
- Ph2NCT02407405 · MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasNational Cancer Institute (NCI) · active not recruiting · Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) · principal investigator
- Ph1NCT02211768 · Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1National Cancer Institute (NCI) · completed · Neurofibromatosis, MPNST · principal investigator
- Ph2NCT02015065 · Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal TumorsNational Cancer Institute (NCI) · completed · GIST · principal investigator
- Ph1/Ph2NCT01610570 · Mithramycin for Children and Adults With Solid Tumors or Ewing SarcomaNational Cancer Institute (NCI) · terminated · Ewing Sarcoma, Sarcoma · principal investigator
- Ph1/Ph2NCT01362803 · AZD6244 Hydrogen Sulfate for Children With Nervous System TumorsNational Cancer Institute (NCI) · active not recruiting · Neurofibromatosis 1, Neurofibromatosis Type 1, NF1 · principal investigator
- Ph1NCT01259479 · Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain TumorsNational Cancer Institute (NCI) · completed · Solid Tumors, Brain Tumors, Brain Metastases · principal investigator
- N/ANCT00924196 · Natural History Study of Patients With Neurofibromatosis Type INational Cancer Institute (NCI) · active not recruiting · Neurofibromatosis Type 1, Malignant Peripheral Nerve Sheath Tumor, Plexiform Neurofibroma · principal investigator
- Ph1NCT00727233 · Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform NeurofibromasNational Cancer Institute (NCI) · completed · Neurofibromatosis Type I, Plexiform Neurofibroma · principal investigator
- Ph1/Ph2NCT00514046 · Vandetanib to Treat Children and Adolescents With Medullary Thyroid CancerNational Cancer Institute (NCI) · completed · Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B · principal investigator
- N/ANCT00340522 · Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug DevelopmentNational Cancer Institute (NCI) · completed · Cancer · principal investigator
- Ph1NCT00321581 · AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous LeukemiaNational Cancer Institute (NCI) · completed · Refractory or Recurrent Solid Tumors, Acute Myelogenous Leukemia · principal investigator
- Ph2NCT00076102 · Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform NeurofibromasNational Cancer Institute (NCI) · completed · Neurofibromatosis 1, Neurofibroma, Plexiform · principal investigator
- N/ANCT00026780 · Eligibility Screening for a NCI Pediatric Oncology Branch Research StudyNational Cancer Institute (NCI) · completed · Ewing Sarcoma, Osteosarcoma, Neuroblastoma · principal investigator
- Ph1NCT00011414 · Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid TumorsNational Cancer Institute (NCI) · completed · Wilms' Tumor, Sarcoma, Adenaocortical Carcinoma · principal investigator
- N/ANCT00006435 · Study of Plexiform Neurofibromas in Neurofibromatosis Type 1National Cancer Institute (NCI) · completed · Plexiform Neurofibromas, NF1 · principal investigator
- N/ANCT00001686 · Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare DiseasesNational Cancer Institute (NCI) · completed · Ewing's Sarcoma, Leukemia, Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.